Opendata, web and dolomites

BioTrace SIGNED

World's First Real-Time Monitoring System for Ablation Procedures

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BioTrace project word cloud

Explore the words cloud of the BioTrace project. It provides you a very rough idea of what is the project "BioTrace" about.

opportunity    procedure    costly    cancer    feasibility    treating    clinical    outside    2017    oncology    solution    game    proven    industry    post    viability    heat    treatment    electrophysiology    estimate    40    liver    recurrence    technique    works    area    minimally    tokyo    biological    million    ta    28    dying    algorithms    resection    alternative    rates    sales    roi    unpredictability    8m    2023    global    intervention    risky    pain    54    outcome    patients    limited    hours    biotrace    time    progression    physicians    neurotomy    300    alerted    reducing    standalone    keeping    invasive    hospital    uth    tissue    gold    ablation    38    commercial    standard    device    surgical    lesion    thermal    revenues    unfit    surgery    foresee    24    undertreatment    ai    predicts    market    complete    cardiac    damage    healthcare    frequently    monitor    margin    university    latest    financial    interventional    smaller    tumours    cells    fifth    arrhythmias    remove    changer    track    knowing    considering    treat    continue    35   

Project "BioTrace" data sheet

The following table provides information about the project.

Coordinator
TECHSOMED MEDICAL TECHNOLOGIES LTD 

Organization address
address: MEIR WEISGAL 2 ST., SCIENCE PARK
city: REHOVOT
postcode: 7632605
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHSOMED MEDICAL TECHNOLOGIES LTD IL (REHOVOT) coordinator 50˙000.00

Map

 Project objective

Cancer treatment resection or surgery is currently the gold standard to remove tumours, but it is risky for patients and a costly process (average cost of €28.000 per surgery). Ablation is a minimally invasive technique and the best alternative to surgery (€1,300). However, its use is still limited to treat patients with smaller tumours or patients unfit for surgery, due to its high unpredictability, as there is currently no way of knowing the extent of the lesion during and after the intervention (cells continue dying for up to 24 hours after the intervention due to thermal effects). Thus, undertreatment or over treatment frequently occur, the latest leading to up to 40% recurrence. Our solution, BioTrace, is the only device able to monitor in real-time the extent of the lesion during the ablation procedure and predicts its outcome 24 hours post-treatment. It works by keeping track of the tissue's biological response to the heat using AI-based algorithms. With BioTrace physicians are alerted when damage is observed outside the surgical margin, which enables them to determine its progression 24 hours after the procedure (as proven in a clinical study conducted with 54 standard TA procedures in University of Tokyo Hospital (UTH)). BioTrace will be a game-changer in the ablation technology industry by improving success rates and reducing costs for the healthcare system. Its market opportunity is large since it can be applied not only in the interventional oncology area, but in other areas, such as electrophysiology (for treating cardiac arrhythmias) and neurotomy (for pain management). We foresee that we will need €3 million to complete phase 2 and reach the liver market as a standalone system. Considering a growth of the global ablation market of 35% (2017-2023), in the fifth year of sales we estimate to reach revenues of 10.8M and a ROI of 0.38. During the feasibility study we will further assess the technical, commercial and financial viability of our project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOTRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOTRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More